Join Our Sept. 9 Virtual Watercooler about "March-In" Rights
AUTM will host an informal virtual gathering on Sept. 9 at 4 p.m. EDT
for tech transfer professionals to discuss recent suggestions surounding the potential COVID-19 treatment remdesivir. Please register to join.
Our informal conversation will focus on how inappropriately using the “march-in” provision of the Bayh-Dole Act will stunt investments in a broad range scientific research that will benefit society now and well into the future. Read our statement
Remdesivir was developed by Gilead Sciences over a decade ago for use against deadly infectious diseases such as SARS. It has shown potential promise as a COVID-19 treatment and is currently in clinical trials. In May 2020, the FDA authorized its emergency use for severely ill COVID patients.